DIN 02480514 — KYMRIAH 600000000 CELLS
KYMRIAH is a suspension of Tisagenlecleucel marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Tisagenlecleucel monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02480514
- Brand name
- KYMRIAH
- Active ingredient
- Tisagenlecleucel
- Strength
- 600000000 CELLS
- Dosage form
- SUSPENSION
- Route
- INTRAVENOUS
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.